References
- AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. Retrieved 25 July 2018, from http://www.amstar.ca/docs/AMSTAR-2.pdf
- Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, et al. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England). 391, 1357–1366.
- Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. 2010. Sertraline versus other antidepressive agents for depression. Cochr Database Syst Rev. 4:Cd006117.
- Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C. 2012. Citalopram versus other anti-depressive agents for depression. Cochr Database Syst Rev. 7:Cd006534.
- Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C. 2009. Escitalopram versus other antidepressive agents for depression. Cochr Database Syst Rev. 2:Cd006532.
- Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, et al. 2011. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 155(11):772–785.
- Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, Van Noord M, Thieda P, Thaler K, Gaynes B. 2011. Drug class reviews. In: Drug class review: second-generation antidepressants: final update 5 report. edition. Portland (OR): Oregon Health & Science University.
- "Investing in treatment for depression and anxiety leads to fourfold return." Retrieved 27 july 2017, from https://www.who.int/en/news-room/detail/13-04-2016-investing-in-treatment-for-depression-and-anxiety-leads-to-fourfold-return.
- Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. 2015. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs. 29(8):695–712.
- Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C. 2013. Fluoxetine versus other types of pharmacotherapy for depression. Cochr Database Syst Rev. 7:Cd004185.
- Montgomery S, Hansen T, Kasper S. 2011. Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharm. 14(02):261–268.
- National Collaborating Centre for Mental H 2010. The nice guideline on the treatment and management of depression in adults. In: Depression: the treatment and management of depression in adults (Updated Edition). Leicester (UK): British Psychological Society
- Omori IM, Watanabe N, Nakagawa A, Akechi T, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, Meta-Analysis of New Generation Antidepressants (MANGA) Study Group 2009. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J Psychopharmacol (Oxford)). 23(5):539–550.
- Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. 2010. Fluvoxamine versus other anti-depressive agents for depression. Cochr Database Syst Rev. 3: Cd006114.
- Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A, Barbui C. 2014. Paroxetine versus other anti-depressive agents for depression. Cochr Database Syst Rev. 4:Cd006531.
- Ramsberg J, Asseburg C, Henriksson M. 2012. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 7(8):e42003.
- Trkulja V. 2010. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J. 51(1):61–73.
- Wang Y, Yu LH, Xie J, Chen JJ, Wei QP. 2014. Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis. Asia Pacific Psychiatry. 6(4):353–362.
- WHO. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO
- World Health Day 2017. How to get involved. http://www.who.int/campaigns/world-health-day/2017/how-to-get-involved/en